Hematologics

Hematologics is a private U.S. hematopathology and specialty diagnostics company focused on blood cancers and related hematologic disorders. The company operates a clinical diagnostic service laboratory offering measurable residual disease testing, multidimensional flow cytometry, cytogenetics, fluorescence in situ hybridization, molecular analysis, next-generation sequencing, SNP/CGH microarray, and cell sorting services. Hematologics is particularly known for its Difference from Normal (∆N:™) flow cytometry approach for residual disease detection in acute leukemia and other hematologic neoplasms. Rather than developing therapeutic drugs, the company provides commercial laboratory testing and interpretive diagnostic services to hospitals, clinicians, and clinical laboratories. Its business is centered on precision diagnostics, disease classification, and treatment monitoring in hematologic oncology.